

Certificate of Analysis

MEK2, unactive

(Recombinant enzyme expressed in Sf21 insect cells)

Item # 14-532, 14-532-K, 14-532M

Parent Lot # 1654882

The data presented in this document apply to the parent lot shown above and to all pack sizes derived from subsequent vialling runs of this parent lot. An alphabetical suffix after the parent lot number is used to denote each vialling run.

Product Description: N-terminal 6His-tagged recombinant, full-length human MEK2 expressed by baculovirus in Sf21 insect cells. Purified using Ni²⁺/NTA agarose. Purity 93.2% by SDS-PAGE and Coomassie blue staining. MW = 46kDa.

Specific Activity: As provided, this lot demonstrated <1% of maximum activity. Activated by phosphorylation with c-Raf (cat# 14-352).

Formulation: 1.778mg/ml of enzyme in 50mM Tris/HCl pH7.5, 150mM NaCl, 0.1mM EGTA, 0.03% Brij-35, 270mM sucrose, 1mM benzamidine, 0.2mM PMSF, 0.1% 2-mercaptoethanol. Frozen solution.

Storage and Stability: On receipt of material store at -70°C. Unopened reagent is stable for a minimum of 6 months from date of shipment when stored at recommended storage temperature. Avoid repeat freeze/thaw cycles. For maximum recovery of product, centrifuge original vial prior to removing the cap.

Handling Recommendations: Rapidly thaw the vial under cold water and immediately place on ice. Aliquot unused material into pre-chilled microcentrifuge tubes and immediately snap-freeze the vials in liquid nitrogen prior to re-storage at -70°C.

**FOR IN VITRO RESEARCH USE ONLY
NOT FOR USE IN HUMANS OR ANIMALS**


Quality Control Testing

Activation Assay: Unactive MEK2 was activated using c-Raf (cat# 14-352). 5.725µg of unactive MEK2 was activated using 183ng of c-Raf, then diluted 500-fold, used to activate MAP kinase 2 and the increased activity of the MAP kinase 2 against MBP determined. The activation of MEK2, subsequent activation of MAP kinase 2 and assay are described on page two. Results of this assay are shown below.

MS Tryptic Fingerprint: Confirmed identity as MEK2 with the translated sequence listed on page four.

SDS-PAGE and Coomassie Stain: Purity was assessed by SDS-PAGE and Coomassie blue staining using 3µg of MEK2, unactive.

Active c-Raf	Unactive MEK2	MBP	Mean cpm	Comments
None	5.725µg	8.25µg	3128	Background
183ng	5.725µg	8.25µg	16719	Kinase activity



Certificate of Analysis

Kinase Assay Protocol

Stock Solutions:

1. **10 x Activation Buffer:** 500mM Tris/HCl pH7.5, 1mM EGTA, 1mM Na₃VO₄, 1% 2-mercaptoethanol, 0.3% Brij-35.
2. **Dilution Buffer:** 50mM Tris/HCl pH7.5, 0.1mM EGTA, 0.1% 2-mercaptoethanol, 0.1mM Na₃VO₄, 1mg/ml BSA.
3. **Stage One 5 x Mg/ATP:** 50mM magnesium acetate, 1mM ATP.
4. **MEK2, unactive (Catalogue# 14-532):** Add to a final assay concentration of 5µM (0.229mg/ml). Dilute with Dilution Buffer to 1.14mg/ml. Add 5µl of stock per assay point.
5. **c-Raf-1, active (Catalogue# 14-352):** Add to a final assay concentration of 0.1µM (7.3µg/ml). Dilute with Dilution Buffer to 73µg/ml. Use 2.5µl of stock per assay point.
6. **MAPK2 (Catalogue# 14-198):** Add to a final assay concentration of 1µM (67µg/ml). Dilute with Dilution Buffer to 0.67mg/ml. Use 2.5µl of stock per assay point.
7. **Stage Two 5 x Mg/ATP:** 50mM magnesium acetate, 0.5mM ATP.
8. **10 x Assay Buffer:** 250mM Tris/HCl pH7.5, 2mM EGTA.
9. **MBP substrate (Catalogue# 13-104):** Use at a final assay concentration of 0.33mg/ml. Prepare a 3.33mg/ml stock. Use 2.5µl of stock per assay point.
10. **[γ-³³P]ATP:** 2.5 x magnesium acetate/[γ-³³P]ATP cocktail: 25mM magnesium acetate and 0.25mM ATP to which is added [γ-³³P]ATP (specific activity approximately 500cpm/pmol as required.)

Assay Procedure:

Stage One: *Activation of MEK2*

1. Add 2.5µl of 10 x activation buffer to a microcentrifuge tube.
2. Add 10µl dH₂O.
3. Add 5µl of **MEK2, unactive**.
4. Add **2.5µl (183ng) c-Raf, active**.
5. Add 5µl stage one 5 x Mg/ATP.
6. In appropriate controls, add dilution buffer to a final volume of 25µl.
7. Incubate for 30 minutes at 30°C.
8. Stop the reaction by diluting the MEK2 500-fold in dilution buffer. Store on ice.

Stage Two: *Activation of MAPK2*

1. Add 2.5µl 10 x activation buffer to a microcentrifuge tube.
2. Add 12.5µl of dH₂O.
3. Add 2.5µl of **MAP kinase 2 (MAPK2)**.
4. Add 2.5µl of diluted **MEK2** from **Stage One** above.
5. Add 5 µl of stage two 5 x Mg/ATP.
6. Incubate for 15 minutes at 30°C.
7. Immediately transfer 1µl of the mixture to the **Stage Three** component mixture.

Certificate of Analysis

Stage Three: *Phosphorylation of MBP by Activated MAP kinase 2.*

1. Add 2.5µl 10 x assay buffer to a microcentrifuge tube.
2. Add 9µl dH₂O.
3. Add 2.5µl **MBP**.
4. Add 1µl of the **Stage Two** reaction product.
5. Add 10µl of the 2.5 x magnesium acetate/ [γ-³³P]ATP cocktail.
6. Incubate for 15 minutes at 30°C.
7. Transfer a 20µl aliquot onto the centre of a 2cm x 2cm **P81** paper.
8. Wash the assay squares twice with 75mM phosphoric acid.
9. Wash the assay squares once for 2 minutes with acetone.
9. Transfer the assay squares to a scintillation vial and add 1ml of scintillation cocktail.
10. Read in a scintillation counter. Compare cpm of enzyme samples with cpm of control samples that contain all assay components plus 1µl of 30% phosphoric acid and control samples with all assay components except c-Raf.

Certificate of Analysis

MEK2 Sequence Information

Protein	human MEK2
Tags	N-terminal 6His
Native sequence	M10 of the fusion protein is equivalent to M1 of human MEK2
Accession number	GenBank NM_030662

Recombinant MEK2 amino acid sequence:

```

1 MHHHHHHEFM LARRKPVLP LARRKPVLP LTINPTIAEG PSPTSEGASE ANLVDLQKKL EELELDEQQK
61 KRLEAFLTQK AKVGELKDDD FERISELGAG NGGVVTKVQH RPSGLIMARK LIHLEIKPAI
121 RNQIIRELQV LHECNTPYIV GFYGFYSDG EISICMEHMD GGSLDQVLKE AKRIPEEILG
181 KVSIAVLRGL AYLREKHQIM HRDVKPSNIL VNSRGEIKLC DFGVSGQLID SMANSFVGTR
241 SYMAPERLQG THYSVQSDIW SMGLSLVELA VGRYPIPPPD AKELEAIFGR PVVDGEEGEP
301 HSISPRPRPP GRPVSQSDIW SRPAMAIFEL LDYIVNEPPP KLPNGVFTPD FQEFVNKCLI
361 KNPAERADLK MLTNHTFIKR SEVEEVDFAG WLCKTLRLNQ PGTPTRTAV
  
```

Recombinant MEK2 nucleotide sequence:

```

1 atgcatcatc accatcacca tgaattcatg ctggcccgga ggaagccggt gctgcccggc
61 ctaccatca accctaccat cgccgagggc ccatccccta ccagcgaggg cgcctccgag
121 gcaaacctgg tggacctgca gaagaagctg gaggagctgg aacttgacga gcagcagaag
181 aagcggctgg aagcctttct caccagaaa gccaaagctg gcgaactcaa agacgatgac
241 ttcgaaagga tctcagagct gggcgcgggc aacggcgggg tggtcaccaa agtccagcac
301 agaccctcgg gcctcatcat gcccaggaag ctgatccacc ttgagatcaa gccggccatc
361 cggaaccaga tcatccgca gctgcaggtc ctgcacgaat gcaactcgcc gtacatcgtg
421 ggcttctacg gggccttcta cagtgcaggg gagatcagca tttgcatgga acacatggac
481 ggcggtctcc tggaccaggt gctgaaagag gccaaagagga ttcccagga gatcctgggg
541 aaagtcagca tcgcggttct ccggggcttg gcgtacctcc gagagaagca ccagatcatg
601 caccgagatg tgaagccctc caacatcctc gtgaactcta gaggggagat caagctgtgt
661 gacttcgggg tgagcggcca gctcatagac tccatggcca actccttcgt gggcacgcgc
721 tcctacatgg ctccggagcg gttgcagggc acacattact cgggtgcagtc ggacatctgg
781 agcatgggccc tgtccctggg ggagctggcc gtcggaaggt accccatccc cccgcccgac
841 gccaaagagc tggaggccat ctttgccggc cccgtggtcg acggggaaga aggagagcct
901 cacagcatct cgcctcggcc gaggcccccc gggcgccccg tcagcgggtc cgggatggat
961 agccggcctg ccatggccat ctttgaactc ctggactata ttgtgaacga gccacctcct
1021 aagctgcccc acggtgtggt cacccccgac ttccaggagt ttgtcaataa atgcctcatc
1081 aagaaccag cggagcgggc ggacctgaag atgctcacia accacacctt catcaagcgg
1141 tccgaggtgg aagaagtgga ttttgccggc tggttgtgta aaaccctgcy gctgaaccag
1201 cccggcacac ccacgcgcac cgccgtgtga
  
```

Reviewed and approved by site quality representative.

Unless otherwise stated in our catalogue or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

© 2014 Eurofins Pharma Discovery Services UK Limited is an independent member of Eurofins Discovery Services.